[HTML][HTML] Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use
R Rockett, K Basile, S Maddocks, W Fong… - … England Journal of …, 2022 - Mass Medical Soc
R Rockett, K Basile, S Maddocks, W Fong, JE Agius, J Johnson-Mackinnon, A Arnott…
New England Journal of Medicine, 2022•Mass Medical SocResistance Mutations after Sotrovimab Use Among the first 100 patients who received
sotrovimab, a monoclonal antibody directed against SARS-CoV-2, at a center in Australia, 8
had persistently positive SARS-CoV-2 polymerase-chain-reaction tests. Isolates obtained
from 4 patients showed a mutation associated with resistance to sotrovimab in the receptor-
binding domain, and cultures were positive at 2 to 3 weeks after treatment.
sotrovimab, a monoclonal antibody directed against SARS-CoV-2, at a center in Australia, 8
had persistently positive SARS-CoV-2 polymerase-chain-reaction tests. Isolates obtained
from 4 patients showed a mutation associated with resistance to sotrovimab in the receptor-
binding domain, and cultures were positive at 2 to 3 weeks after treatment.
Resistance Mutations after Sotrovimab Use
Among the first 100 patients who received sotrovimab, a monoclonal antibody directed against SARS-CoV-2, at a center in Australia, 8 had persistently positive SARS-CoV-2 polymerase-chain-reaction tests. Isolates obtained from 4 patients showed a mutation associated with resistance to sotrovimab in the receptor-binding domain, and cultures were positive at 2 to 3 weeks after treatment.
The New England Journal Of Medicine